Olema Pharmaceuticals Inc
$ 9.75
-0.71%
11 Jun - close price
- Market Cap 857,752,000 USD
- Current Price $ 9.75
- High / Low $ 10.04 / 9.52
- Stock P/E N/A
- Book Value 5.88
- EPS -2.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.43 %
- 52 Week High 36.26
- 52 Week Low 3.89
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Analyst Target Price
$41.36
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-13 | 2025-03-18 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.52 | -0.5044 | -0.49 | -0.51 | -0.36 | -0.51 | -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 |
| Estimated EPS | -0.5153 | -0.5215 | -0.4702 | -0.38 | -0.55 | 0.1732 | -0.58 | -0.55 | -0.55 | -0.48 | -0.51 | -0.73 |
| Surprise | -0.0047 | 0.0171 | -0.0198 | -0.13 | 0.19 | -0.6832 | -0.02 | 0.01 | -0.01 | -0.01 | 0.03 | 0.24 |
| Surprise Percentage | -0.9121% | 3.279% | -4.211% | -34.2105% | 34.5455% | -394.4573% | -3.4483% | 1.8182% | -1.8182% | -2.0833% | 5.8824% | 32.8767% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OLMA
2026-06-10 10:11:01
This article provides detailed financial and performance data for two companies: Olema Pharmaceuticals Inc. (OLMA) and Guardant Health Inc. (GH). For OLMA, it lists a closing price of $9.82 with a 6.03% decrease, noting its market cap, insider ownership, and various performance metrics. For GH, it shows a closing price of $130.70 with a 0.45% increase, detailing its much larger market cap, institutional ownership, and strong year-to-date and yearly performance.
2026-06-10 07:40:27
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US). The article does not provide specific details from the analyst report, such as a price target or the reasons behind the maintained rating.
2026-06-03 20:10:19
Olema Oncology announced that it granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective June 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with a 10-year term and an exercise price of $12.71 per share.
2026-06-03 17:09:15
Olema Oncology announced that it granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock. These grants were made under the Company's 2022 Inducement Plan as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $12.71 per share.
2026-06-03 14:39:02
Olema Pharmaceuticals' valuation is under scrutiny after a new collaboration with Bayer and positive Phase 1 data for OP-3136. Despite a recent share price decline of 25% over 30 days and 56% over 90 days, the stock shows a strong 1-year total return. The company appears undervalued with a P/B ratio of 1.9x and a DCF fair value of $181.73 per share, significantly above its current trading price of $10.69, though sensitivity to clinical success and profitability assumptions is noted for this early-stage biotech.
2026-06-03 14:10:19
Olema Pharmaceuticals (OLMA) is being re-evaluated after a new collaboration with Bayer and positive Phase 1 data for its drug OP-3136. Despite short-term stock price declines (25% in 30 days, 56% in 90 days), the company's P/B ratio of 1.9x suggests it's undervalued compared to its peers (3.7x) and the broader biotech industry (2.6x). A discounted cash flow (DCF) model further indicates significant undervaluation, estimating a fair value of $181.73 per share against a current price of $10.69, though this relies on future assumptions for a clinical-stage, loss-making company.
